Anti-CRISPR Polypeptide Delivery for Cell Cytosol
Summary
USPTO published patent application US20260109737A1 on April 23, 2026, covering engineered Anti-CRISPR (Acr) polypeptides and delivery systems engineered for delivery to the cytosol and/or nucleus of cells. The application names five inventors: Amit Choudhary, Axel O. Vera, Bradley Pentelute, Nicholas Truex, and Ronald T. Raines, with a filing date of August 20, 2025 and application number 19304906. CPC classifications span C07K 14/005, C07K 14/32, C07K 14/34, and related subclasses covering peptide and nucleic acid delivery technologies.
“In certain embodiments, an engineered Acr polypeptide comprises an Acr polypeptide operatively coupled to a cargo delivery molecule, wherein the cargo delivery molecule is capable of binding or otherwise interacting with a pore-forming polypeptide.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
USPTO published patent application US20260109737A1 covering engineered Anti-CRISPR (Acr) polypeptides operatively coupled to cargo delivery molecules capable of binding pore-forming polypeptides, enabling delivery to the cytosol and nucleus of cells. The application discloses methods of Acr delivery via these engineered systems.
For biotechnology and pharmaceutical companies developing gene-editing technologies, this patent application represents prior art that may affect freedom-to-operate analyses for CRISPR-related delivery systems. Companies working with anti-CRISPR proteins or cytosolic delivery mechanisms should review the claims for potential overlap with their own R&D programs.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
ANTI-CRISPR DELIVERY COMPOSITIONS AND METHODS
Application US20260109737A1 Kind: A1 Apr 23, 2026
Inventors
Amit Choudhary, Axel O. Vera, Bradley Pentelute, Nicholas Truex, Ronald T. Raines
Abstract
Described in certain exemplary embodiments herein are engineered Anti-CRISPR (Acr) polypeptides and delivery systems engineered for delivery to the cytosol and/or nucleus of cells. In certain embodiments, an engineered Acr polypeptide comprises an Acr polypeptide operatively coupled to a cargo delivery molecule, wherein the cargo delivery molecule is capable of binding or otherwise interacting with a pore-forming polypeptide. Also described in certain exemplary embodiments are methods of Acr delivery to cells via the engineered Acr polypeptides and delivery systems of the present disclosure.
CPC Classifications
C07K 14/005 C07K 14/32 C07K 14/34 C12N 9/99 C07K 2319/09 C07K 2319/55 C12N 2795/00022
Filing Date
2025-08-20
Application No.
19304906
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.